Dr. Matthew Howard Abramson, MD

Dr. Abramson practices at Mount Sinai Medical Center in Miami Beach, Florida, part of Mount Sinai Medical Center of Florida.

Dr. Abramson's NPI, 1790104560, was assigned on April 9, 2014. Dr. Abramson holds New York license 295948.

Dr. Abramson's primary practice is Mount Sinai Medical Center, at 4300 Alton Rd, Miami Beach, FL 33140 in Miami-Dade County. The practice phone is (305) 674-2121. Dr. Abramson also practices at Mount Sinai Medical Center, 5 E 98th St, New York, NY 10029.

Dr. Abramson's primary practice is Mount Sinai Medical Center in Miami Beach, Florida, part of Mount Sinai Medical Center of Florida. Dr. Abramson is also affiliated with The Mount Sinai Hospital. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Dr. Abramson to 1 more dialysis center, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Abramson practices, 3 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Abramson's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Abramson is board certified in internal medicine by the American Board of Internal Medicine. Dr. Abramson is licensed in New York.

Dmand AI lists acute kidney failure, chronic kidney disease, fluid and electrolyte imbalances and gout among the conditions Dr. Abramson treats.

CMS data shows 858 Medicare services from Dr. Abramson across 10 procedure codes in 2024, for 245 Medicare patients. Medicare paid $70,094 for them.

CMS counts 245 Medicare patients who saw Dr. Abramson in 2024. The largest group is 65 to 74, with 91 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 42% are also on Medicaid. Their average risk score is 5.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Abramson's median patient age at 67, with 48% women.

In 2024, Dr. Abramson wrote 714 Medicare Part D claims for 142 patients. 72% of them were for generic drugs. CMS names the drug for 564 of them, across 19 drugs with 11 or more claims each, at $222,740 in total drug cost. In 2023, CMS named 514 claims across 16 drugs.

Dr. Abramson accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Abramson as offering telehealth.

Dmand AI links 11 papers to Dr. Abramson, published from 2021 to 2024. 2021 was the busiest year, with 2. The most frequent topics are Kidney Glomerulus. Dr. Abramson's most frequent co-authors are Victoria Gutgarts, Ilya G. Glezerman, MD and Ala Abudayyeh, MD.

CMS Open Payments shows 16 general payments to Dr. Abramson from 5 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 100% of the total. Relypsa, Inc. paid the most, $282.

Dr. Abramson is in network with 16 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.